BMO Capital Starts Nightstar Therapeutics (NITE) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wedbush Starts Nightstar Therapeutics (NITE) at Outperform
October 23, 2017 6:17 AM EDTWedbush initiates coverage on Nightstar Therapeutics (NASDAQ: NITE) with a Outperform rating and a price target of $29.00.
Analyst David Nierengarten views shares as undervalued, given NITEs lead asset, NSR-REP1, is set to enter Ph 3 with curative potential for choroideremia (CHM), a rare... More
UPDATE: Leerink Partners Starts Nightstar Therapeutics (NITE) at Outperform
October 23, 2017 6:13 AM EDT(Updated - October 23, 2017 7:45 AM EDT)
(updated to expand analyst comment)
Leerink Partners initiates coverage on Nightstar Therapeutics (NASDAQ: NITE) with a Outperform rating and a price target of $25.00.
Analyst Joseph Schwartz called it a 'White Night' for Retinal Dystrophies. The... More
Jefferies Starts Nightstar Therapeutics (NITE) at Buy
October 23, 2017 3:13 AM EDTJefferies initiates coverage on Nightstar Therapeutics (NASDAQ: NITE) with a Buy rating and a price target of $25.00.
Analyst Michael Yee likes the pure-play profile and the company's differentiation through a sole focus on retinal diseases. The analyst believes the company pivotal Phase 3... More
